Medicare Enrolled

Dr. Sumalatha Patibandla, MD

Medical Oncology · Beaumont, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3070 COLLEGE ST, Beaumont, TX 77701
4098131686
In practice since 2006 (19 years)
NPI: 1699713198 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Patibandla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patibandla? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Patibandla

Dr. Sumalatha Patibandla is a medical oncology in Beaumont, TX, with 19 years in practice. Based on federal Medicare data, Dr. Patibandla performed 38,900 Medicare services across 3,134 unique beneficiaries.

Between the years covered by Open Payments, Dr. Patibandla received a total of $1,557 from 29 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Patibandla is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 23% volume in TX$ $1,557 industry payments

Medicare Practice Summary

Medicare Utilization ↗
38,900
Medicare services
Top 23% in TX for medical oncology
3,134
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,047 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron sucrose injection (Venofer)14,700$0$2
Darbepoetin injection (Aranesp) for anemia8,920$2$20
Pembrolizumab injection (Keytruda)6,000$43$137
Dexamethasone injection (steroid)1,393$0$1
Complete blood count (CBC) with differential1,105$8$36
Comprehensive metabolic blood panel957$10$64
Office visit, established patient (30-39 min)717$90$368
Lactate dehydrogenase (enzyme) level472$6$31
Blood draw (venipuncture)467$8$20
Magnesium level test423$7$29
Iron level test382$6$27
Iron binding capacity test382$9$35
Injection, granisetron hydrochloride, 100 mcg380$0$24
Anti-nausea injection (Aloxi/palonosetron)380$1$114
Office visit, established patient (20-29 min)276$57$250
Injection of additional new drug or substance into vein175$11$108
Administration of chemotherapy into vein, 1 hour or less175$95$707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less151$21$157
Complete blood count (CBC), automated141$6$34
Microscopic examination for white blood cells with manual cell count140$4$22
Drug injection, under skin or into muscle132$10$96
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less120$43$313
Ferritin level test (iron stores)96$13$60
New patient office visit (45-59 min)91$112$565
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle89$52$211
Hospital follow-up visit, moderate complexity86$59$247
Injection, diphenhydramine hcl, up to 50 mg83$1$7
Red blood count, automated test74$4$23
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries54$91$657
Stool analysis for blood to screen for colon tumors48$4$24
Unclassified drugs46$1$8
Nuclear medicine study from skull base to mid-thigh with ct scan44$1,077$4,802
Administration of chemotherapy into vein, each additional hour39$21$161
Office visit, established patient, complex (40-54 min)37$126$496
Reticulated (young) platelet measurement36$35$143
Administration of additional new drug or substance into vein, 1 hour or less34$46$344
Initial hospital admission, moderate complexity21$99$470
Biopsy and aspiration of bone marrow sample for diagnosis20$118$523
New patient office visit, complex (60-74 min)14$166$709
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
83.6% medium
15.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,557
Total received (2018-2024)
Avg $260/year across 6 years
Bottom 34% in TX for medical oncology
29
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,509 (96.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$48 (3.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$762
2023
$266
2022
$28
2021
$50
2019
$176
2018
$275

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
BeiGene USA, Inc.
$145
AstraZeneca Pharmaceuticals LP
$123
PFIZER INC.
$114
Gilead Sciences, Inc.
$110
Merck Sharp & Dohme LLC
$108
Boston Scientific Corporation
$84
Boehringer Ingelheim Pharmaceuticals, Inc.
$82
Puma Biotechnology, Inc.
$82
SOBI, INC
$81
Lilly USA, LLC
$78
GENZYME CORPORATION
$66
Incyte Corporation
$61
Eisai Inc.
$59
PUMA BIOTECHNOLOGY, INC.
$41
Janssen Biotech, Inc.
$32
GlaxoSmithKline, LLC.
$31
Tempus AI, Inc
$29
E.R. Squibb & Sons, L.L.C.
$28
PharmaEssentia USA Corporation
$28
Genentech USA, Inc.
$26
Celgene Corporation
$24
Genmab U.S., Inc.
$23
TAIHO ONCOLOGY, INC.
$21
Regeneron Healthcare Solutions, Inc.
$17
MorphoSys, US Inc.
$17
Astellas Pharma US Inc
$14
Takeda Pharmaceuticals U.S.A., Inc.
$12
Amgen Inc.
$12
Clovis Oncology, Inc.
$11
Top 3 companies account for 24.6% of total payments
Associated products mentioned in payments ›
BESPONSA · BESREMI · BRUKINSA · ELIQUIS · ENJAYMO · Epkinly · GAZYVA · GILOTRIF · IBRANCE · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · MONJUVI · NINLARO · Nerlynx · OJJAARA · PADCEV · Pomalyst · RYBREVANT · Rubraca · SARCLISA · VERZENIO · VONJO · XT CDX · Xtandi · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $4 per 100 Medicare services performed
Looking for a medical oncology in Beaumont?
Compare medical oncologys in the Beaumont area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
6
Per 100K population
2.4
County median income
$59,934
Nearest hospital
BAPTIST BEAUMONT HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Patibandla is a mixed practice specialist, with above-average Medicare volume (top 23% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Patibandla experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Patibandla performed 14,700 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patibandla receive payments from pharmaceutical companies?
Yes. Dr. Patibandla received a total of $1,557 from 29 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patibandla's costs compare to other medical oncologys in Beaumont?
Dr. Patibandla's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patibandla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →